September 21, 2019
7 min watch

VIDEO: Insights on optimal antithrombotic strategy in patients with diabetes, stable CAD

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

PARIS — In this video exclusive, Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital, professor of medicine at Harvard Medical School and Cardiology Today Editorial Board Member, provides a deep dive on the THEMIS and THEMIS-PCI trials presented at the European Society of Cardiology Congress.

“THEMIS is the largest trial of diabetes performed to date and THEMIS-PCI is the largest group of patients with diabetes and stents to date,” Bhatt told Healio.

THEMIS evaluated ticagrelor (Brilinta, AstraZeneca) added to low-dose aspirin, compared with aspirin alone, in patients with diabetes and stable CAD, but no history of MI or stroke. THEMIS-PCI, the prespecified subgroup analysis, looked at dual antiplatelet therapy vs. aspirin alone in patients with a history of PCI.

Bhatt provides an overview and interpretation of the findings.

Watch the video for more.